Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast c

[News]

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

More... (http://www.news-medical.net/news/20121206/Bio-Path-to-initiate-BP-100-101-Phase-I-trial-for-treatment-of-two-types-of-breast-cancer.aspx)